Gavin, thank you so much for posting this link.
I quickly read all abstracts about CC. This one caught my attention:
Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO)
http://abstract.asco.org/AbstView_114_100116.html
Quote:
Conclusions:
GEMOX-cetuximab regimen was well tolerated and met its primary endpoint (4-month PFS ≥60%). However, median PFS and OS were similar in both arms. Exploratory analyses (e.g., KRAS tumor status) are underway to identify pt subgroups deriving benefit from the addition of cetuximab to CTx.
Bold font is mine.
It’s disappointing to see that GEMOX+cetuximab failed to show advantage over GEMOX alone. Up until now, GEMOX+cetuximab seemed to be the most promising new protocol.